Thursday, June 02, 2016 4:39:39 PM
Submit Release
EIN News
Thursday, June 2, 2016
Get RSS Feed Submit Release
Menu > All News Topics ; Press Releases by Industry Channel
Zecuity (sumatriptan) Migraine Patch: Drug Safety Communication - FDA Evaluating Risk of Burns and Scars
[Posted 06/02/2016]
AUDIENCE: Internal Medicine, Pain Management, Neurology, Pharmacy
ISSUE: FDA is investigating the risk of serious burns and potential permanent scarring with the use of Zecuity (sumatriptan iontophoretic transdermal system) patch for migraine headaches. Since marketing of the Zecuity patch began in September 2015, a large number of patients have reported they experienced burns or scars on the skin where the patch was worn. The reports included descriptions of severe redness, pain, skin discoloration, blistering, and cracked skin. As a result, FDA is investigating these serious adverse events to determine whether future regulatory action is needed, and will update the public with new information when the FDA review is complete.
BACKGROUND: The Zecuity patch contains the active ingredient sumatriptan, a prescription medicine used to treat acute migraine headaches in adults. The patch delivery system is designed to deliver a dose of medicine by way of a single-use, battery-powered patch that is wrapped around the upper arm or thigh. It should remain in place for no longer than four hours.
RECOMMENDATION: Patients who experience moderate to severe pain at the Zecuity patch site should immediately remove it to avoid possible burns or scarring, regardless of how long the patch has been worn, and contact your health care professional. Do not bathe, shower, or swim while wearing the patch. Read the Patient Information leaflet and the Instructions for Use section in the drug label, and talk with your health care professional if you have any questions or concerns.
Health care professionals should advise patients who complain of moderate to severe pain at the application site to remove the Zecuity patch immediately. Consider a different formulation of sumatriptan or switch these patients to an alternative migraine medicine. Evaluate patients and the application site as needed.
Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of this product to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:
Complete and submit the report Online: www.fda.gov/MedWatch/report
Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
[06/02/2016 - Drug Safety Communication - FDA]
Powered by EIN Presswire
Distribution channels: Healthcare & Pharmaceuticals
Submit your press release
articles: 329,116,643
readers: 3,929,694
Got News to Share? Click here.
EIN Presswire
Submit a press release · See all
Newsfeed Maker
NewsPlugin
Email News Alerts
Datamine from our index of 250 million articles – updated in real time – and have headlines emailed to you. An affordable clipping service with advanced easy-to-use tools to customize your topics.
Press Releases
Do you have news to share? Plug your news into the daily news cycle with EIN Presswire. Your news IS news. Our users are monitoring specific topics – they can't go to thousands of websites – so they rely on EIN Newsdesk to sort and filter news which matches their specific interests. Match it up to those who care.
Publications
Access dozens of industry publications managed by EIN News. Get news relevant to your Industry or Profession. Our news is aggregated from thousands of sources and organized for you. Find events and conferences that match your interest and read press releases before your competition.
Events & Conferences
EIN Newsdesk is a “Go-To” destination for journalists and other professionals world-wide who are deeply involved in very specific topics. Our vertical niche publications reach industry leaders and decision makers who meet at conferences. Upload your event today.
RSS News Feeds
Stream live news headlines to your website, blog or applications. Get RSS feeds on a variety of news topics maintained by our editors or create your custom newsfeeds on any topic. You'll get a truly customized output.
News Topics
All News Topics
News by Country
News by U.S. State
Newsletters
Create Newsletter
Search Newsletters
Browse Newsletters
Press Releases
Submit Release
Browse Featured Releases
Browse All Releases
Events & Conferences
Create Event
Search Events
Browse Events
RSS Feeds
Create RSS Feed
Search RSS Feeds
Browse RSS Feeds
Other Services
World Media Directory
NewsPlugin for Wordpress
Blog Op/Ed
Questions?
About EIN Newsdesk
How-to Videos
User Agreement
Privacy Policy
Contact
Login
Sign Up
EIN Newsdesk & EIN Presswire (a press release distribution service)
Follow us on Facebook & Twitter and connect with us on LinkedIn
IPD Group, Inc., 1025 Connecticut Avenue NW, Suite 1000, Washington, DC 20036 · Contact · About
© 1995-2016 IPD Group, Inc., a publisher of EIN News · All Rights Reserved · Privacy Policy · User Agreement
=
Recent PATH News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/17/2024 10:16:28 PM
- UiPath State of the Automation Professional Report Highlights 2024 as the Year of AI Integration • Business Wire • 09/16/2024 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/13/2024 08:24:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/13/2024 08:17:26 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/11/2024 08:20:55 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/06/2024 09:13:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/06/2024 08:14:27 PM
- Broadcom Down 10% Post-Earnings, UiPath Up 8%; Qualcomm Eyes Intel Assets; Salesforce Acquires Own Company • IH Market News • 09/06/2024 11:59:00 AM
- Form 3/A - Initial statement of beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 09/05/2024 11:19:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/05/2024 08:17:42 PM
- UiPath Reports Second Quarter Fiscal 2025 Financial Results • Business Wire • 09/05/2024 08:10:00 PM
- UiPath Chief Financial Officer Ashim Gupta Takes on Expanded Role as Chief Operating Officer • Business Wire • 09/05/2024 08:10:00 PM
- UiPath Appoints S. Somasegar to its Board of Directors • Business Wire • 09/05/2024 08:10:00 PM
- U.S. Index Futures Steady Amid Labor Data Anticipation; Oil Prices Rise • IH Market News • 09/05/2024 10:13:05 AM
- UiPath Unveils Partner Sponsors for FORWARD, the Largest Global Event for Automation and AI Practitioners • Business Wire • 09/04/2024 02:30:00 PM
- UiPath to Participate in the Piper Sandler Growth Frontiers Conference • Business Wire • 09/03/2024 08:10:00 PM
- UiPath Named a Leader in Everest Group Digital Interaction Intelligence Products PEAK Matrix® Assessment 2024 • Business Wire • 08/26/2024 12:33:00 PM
- UiPath, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before August 19, 2024 to Discuss Your Rights - PATH • PR Newswire (US) • 08/19/2024 09:45:00 AM
- UiPath, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before August 19, 2024 to Discuss Your Rights - PATH • PR Newswire (US) • 08/15/2024 09:45:00 AM
- UiPath Recognized as a Leader in the 2024 Gartner Magic Quadrant for Robotic Process Automation • Business Wire • 08/12/2024 03:56:00 PM
- Lost Money on UiPath, Inc.(PATH)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 08/12/2024 09:30:00 AM
- UiPath Announces Second Quarter Fiscal 2025 Financial Results Conference Call • Business Wire • 08/08/2024 08:10:00 PM
- The Gross Law Firm Reminds UiPath Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 19, 2024 - PATH • PR Newswire (US) • 08/08/2024 09:45:00 AM
- UiPath Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PATH • PR Newswire (US) • 08/06/2024 02:00:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM